Telcyta: Phase II interim data

In a Phase II trial of Telcyta plus Doxil in 13 evaluable patients, 46% had an objective response and 77% had disease control. Johnson & Johnson (JNJ, New Brunswick, N.J.) markets Doxil liposomal do...